Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats

Hypertension Research

Volumn 36, Issue 10, 2013, Pages 866-872

  Thandapilly, Sijo Joseph ^a,b   Louis, Xavier Lieben ^a,b   Behbahani, John ^b   Movahed, Ali ^c   Yu, Liping ^a,d   Fandrich, Robert ^b   Zhang, Shetuan ^e   Kardami, Elissavet ^b   Anderson, Hope D ^a,b   Netticadan, Thomas ^a,b,d  

^a The Inst of Cardiovascular Sciences   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AGRICULTURE AND AGRI FOOD CANADA   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

Cardiovascular; Hydralazine; Hypertrophy; Resveratrol; Spontaneously hypertensive rat

Indexed keywords

HYDRALAZINE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ELECTROCARDIOGRAPHY; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HYPERTENSION; INFLAMMATION; LOW DRUG DOSE; MALE; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEMODYNAMICS; HYDRALAZINE; HYPERTENSION; MALE; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STILBENES;

EID: 84885119071     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.55     Document Type: Article

References (37)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
2. Purushothaman S, Renuka Nair R, Harikrishnan VS, Fernandez AC. Temporal relation of cardiac hypertrophy, oxidative stress, and fatty acid metabolism in spontaneously hypertensive rat. Mol Cell Biochem 2012; 351: 59-64.
3. Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977; 11: 427-433.
4. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health-a comprehensive review of human clinical trials. Mol Nutr Food Res 2011; 55: 1129-1141.
5. Wu JM, Hsieh TC, Wang Z. Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues. Am J Cardiovasc Dis 2011; 1: 38-47.
6. Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 2012; 113: 752-759.
7. Juric D, Wojciechowski P, Das DK, Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007; 292: H2138-H2143.
8. Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D, Kopilas MA, Anderson HD, Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010; 23: 192-196.
9. Wojciechowski P, Juric D, Louis XL, Thandapilly SJ, Yu L, Taylor C, Netticadan T. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J Nutr 2010; 140: 962-968.
10. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck Jr. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009; 119: 1643-1652.
11. Liu Z, Song Y, Zhang X, Zhang W, Mao W, Wang W, Cui W, Jia X, Li N, Han C, Liu C. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 2005; 32: 1049-1054.
12. Liu ZP, Song Y, Liu ZQ, Zhang XP. [Preventive effect of trans-resveratrol on hypertension-induced cardiac hypertrophy in partially nephrectomized rats]. Wei Sheng Yan Jiu 2005; 34: 756-758.
13. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 2005; 38: 243-257.
14. Thandapilly SJ, Louis XL, Yang T, Stringer DM, Yu L, Zhang S, Wigle J, Kardami E, Zahradka P, Taylor C, Anderson HD, Netticadan T. Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. Eur J Pharmacol 2011; 668: 217-224.
15. Onaka U, Fujii K, Abe I, Fujishima M. Antihypertensive treatment improves endothelium- dependent hyperpolarization in the mesenteric artery of spontaneously hypertensive rats. Circulation 1998; 98: 175-182.
16. Cipolla MJ, Smith J, Bishop N, Bullinger LV, Godfrey JA. Pregnancy reverses hypertensive remodeling of cerebral arteries. Hypertension 2008; 51: 1052-1057.
17. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volumepressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008; 21: 1288-1291.
18. Cantor EJ, Babick AP, Vasanji Z, Dhalla NS, Netticadan T. A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J Mol Cell Cardiol 2005; 38: 777-786.
19. Short D. Morphology of the intestinal arterioles in chronic human hypertension. Br Heart J 1966; 28: 184-192.
20. Sharifi AM, Li JS, Endemann D, Schiffrin EL. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1998; 16: 457-466.
21. Falloon BJ, Bund SJ, Tulip JR, Heagerty AM. In vitro perfusion studies of resistance artery function in genetic hypertension. Hypertension 1993; 22: 486-495.
22. Laurant P, Touyz RM, Schiffrin EL. Effect of pressurization on mechanical properties of mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res 1997; 34: 117-125.
23. Louis XL, Thandapilly SJ, Mohankumar SK, Yu L, Taylor CG, Zahradka P, Netticadan T. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J Nutr Biochem 2011; 23: 1163-1169.
24. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 2002; 39: 969-975.
25. Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011; 2011: 495349.
26. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006; 290: H2417-H2423.
27. Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 2005; 288: H1131-H1138.
28. Wang S, Wang X, Yan J, Xie X, Fan F, Zhou X, Han L, Chen J. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway. Eur J Pharmacol 2007; 567: 26-35.
29. Mulvany MJ. Small artery remodeling and significance in the development of hypertension. News Physiol Sci 2002; 17: 105-109.
30. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999; 33 (1 Pt 2), 569-574.
31. Behbahani J, Thandapilly SJ, Louis XL, Huang Y, Shao Z, Kopilas MA, Wojciechowski P, Netticadan T, Anderson HD. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens 2010; 23: 1273-1278.
32. Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? Int J Inflam 2011; 2011: 514623.
33. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593.
34. Vaziri ND. Causal link between oxidative stress, inflammation, and hypertension. Iran J Kidney Dis 2008; 2: 1-10.
35. Moreno JJ. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and T6 fibroblast growth. J Pharmacol Exp Ther 2000; 294: 333-338.
36. Zhong LM, Zong Y, Sun L, Guo JZ, Zhang W, He Y, Song R, Wang WM, Xiao CJ, Lu D. Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS ONE 2012; 7: 32195.
37. Busch F, Mobasheri A, Shayan P, Lueders C, Stahlmann R, Shakibaei M. Resveratrol modulates interleukin-1b-induced phosphatidylinositol 3-kinase and nuclear factor kb signaling pathways in human tenocytes. J Biol Chem 2012; 287: 38050-38063.